Clinical Research
Enhance Your Clinical Studies with RetInSight's AI-Powered Software Solutions
cAIre – center for AI reading excellence
At RetInSight, we specialize in transforming clinical trials through advanced AI-driven software that automates the diagnosis and monitoring of retinal disease biomarkers via Optical Coherence Tomography (OCT).
RetInSight cAIre – "center for AI reading excellence" – supports biotechnology and pharmaceutical companies in their clinical development for retinal diseases, e.g. geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Our solutions provide unparalleled precision, efficiency, and insights, making clinical trials more robust, faster, and cost-effective.
Why choose RetInSight for your clinical trial?
Integrating AI into your clinical trials offers significant advantages, including fully automated, quantitative, and reproducible readouts that surpass human expert assessments. By leveraging AI to gain new insights from existing real-world data, you can reduce overall study costs, accelerate study timelines, and ultimately increase your trial’s success rate.
Embrace AI-driven solutions to streamline your research and achieve impactful results.
From manual grading to fully-automated AI analysis of OCT images
With cAIre, you can overcome the limitations of traditional manual reading centers.
Unlike manual grading, which is confined to limited fields, thickness measurements, and prone to inter-reader variability, cAIre utilizes AI-based segmentation that is guided by human ground truth, ensuring precise and consistent results.
AI solutions for every stage of your study
AI tools for all stages of a clinical study, prospective and retrospective
In prospective clinical studies
In your prospective clinical studies, the RetInSight AI tools are available for
- pre-screening of patients already filtering the optimal patient cohort based on historical data sets,
- real-time screening at sites streamlining the patient selection process and saving valuable time and money,
- monitoring your patients throughout the study allowing an increased doctor-patient communication,
- and additional AI analysis at the end of the study to optimally leverage and substantiate your data set, favourably impacting your differentiation.
AI tools for all stages of a clinical study, prospective and retrospective
For retrospective analysis
In case you have your (interim or final) OCT data set in hands and think about the next step, RetInSight offers to generate insights via retrospective analysis for data substantiation, thus, potentially increasing the success rate of your subsequent clinical studies.
Elevate your clinical trial with AI-based reading excellence
At RetInSight, we are specialized in AI-based reading services. However, we also act as a central reading center by collaborating with world-class manual reading centers providing traditional manual grading of e.g. fundus photography (FP), fluorescein angiography (FA), fundus autofluorescence (FAF) images.
Interested in learning how we can support YOUR study? Contact us, because we cAIre about your clinical study!